Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
Elajami TK, Alfaddagh A, Lakshminarayan D, Soliman M, Chandnani M, Welty FK
Journal of the American Heart Association · 40 citations
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Possibly industry funded
Based on full-text disclosure statement.
Publication
- Published
- 2017-07-01 · J Am Heart Assoc · vol. 6 · issue 7
- Publisher
- Wiley
- Cited
- 51 citations · more than 92% of similar papers · 3.2× the field average
- Impact
- Top 10% most cited in its field
- References
- 70 works
- Access
- Open access (journal) · CC-BY-NC-ND
- Research areas
- Fatty Acid Research and Health · Natural Products and Biological Research · Eicosanoids and Hypertension Pharmacology
- Keywords
- Medicine, Albuminuria, Internal medicine, Angiotensin receptor, Eicosapentaenoic acid, Diabetes mellitus, Endocrinology, Docosahexaenoic acid, Angiotensin-converting enzyme, Coronary artery disease, Type 2 Diabetes Mellitus, Creatinine, Angiotensin II, Blood pressure, Polyunsaturated fatty acid, Fatty acid
- MeSH
- humans, diabetic nephropathies, albuminuria, hypertension, diabetes mellitus, type 2, disease progression, docosahexaenoic acids, eicosapentaenoic acid, drug combinations, angiotensin ii type 1 receptor blockers, angiotensin-converting enzyme inhibitors, treatment outcome, risk factors, prospective studies, time factors, dietary supplements, adult, aged, aged, 80 and over, middle aged, boston, female, male, coronary artery disease
6 authors
From US
- Tarec K. ElajamiBeth Israel Deaconess Medical Center; Harvard University
- Abdulhamied AlfaddaghBeth Israel Deaconess Medical Center; Harvard University
- Dharshan LakshminarayanBeth Israel Deaconess Medical Center; Harvard University
- Michael Y. SolimanBeth Israel Deaconess Medical Center; Harvard University
- Madhuri ChandnaniBeth Israel Deaconess Medical Center; Harvard University
- Francine K. WeltyBeth Israel Deaconess Medical Center; Harvard University
Abstract
Background
Albuminuria is a marker of inflammation and an independent predictor of cardiovascular morbidity and mortality. The current study evaluated whether eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation attenuates progression of albuminuria in subjects with coronary artery disease.
Methods and results
Two-hundred sixty-two subjects with stable coronary artery disease were randomized to either Lovaza (1.86 g of EPA and 1.5 g of DHA daily) or no Lovaza (control) for 1 year. Percent change in urine albumin-to-creatinine ratio (ACR) was compared. Mean (SD) age was 63.3 (7.6) years; 17% were women and 30% had type 2 diabetes mellitus. In nondiabetic subjects, no change in urine ACR occurred in either the Lovaza or control groups. In contrast, ACR increased 72.3% (PPr=0.394, P=0.01).
Conclusions
EPA and DHA supplementation attenuated progression of albuminuria in subjects with type 2 diabetes mellitus and coronary artery disease, most of whom were on an angiotensin-converting enzyme-inhibitor or angiotensin-receptor blocker. Thus, EPA and DHA supplementation should be considered as additional therapy to an angiotensin-converting enzyme-inhibitor or angiotensin-receptor blocker in subjects with type 2 diabetes mellitus and coronary artery disease.
Clinical trial registration
URL: http://www.clinicaltrials.gov. Unique identifier: NCT01624727.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY-NC-ND).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.